Enprostil
- A02BB02 (WHO)
- methyl 7-[(1S,2S,3S)-3-hydroxy-2-[(3R)-3-hydroxy-4-phenoxybut-1-enyl]-5-oxocyclopentyl]hepta-4,5-dienoate
- 73121-56-9 Y
- 5311225
- 4470744
- J4IP5Z9DAU
- D01891 Y
- Interactive image
- COC(=O)CCC=C=CC[C@@H]1[C@H]([C@@H](CC1=O)O)/C=C/[C@H](COc2ccccc2)O
- InChI=1S/C23H28O6/c1-28-23(27)12-8-3-2-7-11-19-20(22(26)15-21(19)25)14-13-17(24)16-29-18-9-5-4-6-10-18/h3-7,9-10,13-14,17,19-20,22,24,26H,8,11-12,15-16H2,1H3/b14-13+/t2?,17-,19-,20-,22-/m1/s1
- Key:PTOJVMZPWPAXER-VFJVYMGBSA-N
Enprostil is a synthetic prostaglandin designed to resemble dinoprostone. Enprostil was found to be a highly potent inhibitor of gastric HCl secretion.[1] It is an analog of prostaglandin E2 but unlike this prostaglandin, which binds to and activates all four cellular receptors viz., EP1, EP2, EP3, and EP4 receptors, enprostil is a more selective receptor agonist in that it binds to and activates primarily the EP3 receptor.[2] Consequently, enprostil is expected to have a narrower range of actions that may avoid some of the unwanted side-effects and toxicities of prostaglandin E2. A prospective multicenter randomized controlled trial conducted in Japan found combining enprostil with cimetidine was more effective than cimetidine alone in treating gastric ulcer.[3]
See also
References
- ^ Roszkowski AP, Garay GL, Baker S, Schuler M, Carter H (November 1986). "Gastric antisecretory and antiulcer properties of enprostil, (+/-)-11 alpha, 15 alpha-dihydroxy-16-phenoxy-17,18,19,20-tetranor-9-oxoprosta- 4,5,13(t)-trienoic acid methyl ester". The Journal of Pharmacology and Experimental Therapeutics. 239 (2): 382–389. PMID 3095537.
- ^ Moreno JJ (February 2017). "Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis". European Journal of Pharmacology. 796: 7–19. doi:10.1016/j.ejphar.2016.12.004. PMID 27940058. S2CID 1513449.
- ^ Murata H, Kawano S, Tsuji S, Tsujii M, Hori M, Kamada T, et al. (2005). "Combination of enprostil and cimetidine is more effective than cimetidine alone in treating gastric ulcer: prospective multicenter randomized controlled trial". Hepato-Gastroenterology. 52 (66): 1925–1929. PMID 16334808.
Further reading
- Toshina K, Hirata I, Maemura K, Sasaki S, Murano M, Nitta M, et al. (December 2000). "Enprostil, a prostaglandin-E(2) analogue, inhibits interleukin-8 production of human colonic epithelial cell lines". Scandinavian Journal of Immunology. 52 (6): 570–575. doi:10.1046/j.1365-3083.2000.00815.x (inactive 2024-04-24). PMID 11119262.
{{cite journal}}
: CS1 maint: DOI inactive as of April 2024 (link) - Tari A, Hamada M, Kamiyasu T, Sumii K, Haruma K, Inoue M, et al. (August 1997). "Effect of enprostil on omeprazole-induced hypergastrinemia and inhibition of gastric acid secretion in peptic ulcer patients". Digestive Diseases and Sciences. 42 (8): 1741–1746. doi:10.1023/A:1018825902055. PMID 9286243. S2CID 25069361.
- Ching CK, Lam SK (October 1995). "A comparison of two prostaglandin analogues (enprostil vs misoprostol) in the treatment of acute duodenal ulcer disease". Journal of Gastroenterology. 30 (5): 607–614. doi:10.1007/BF02367786. PMID 8574332. S2CID 6288648.
- v
- t
- e
analogues ("-prost-")
- Misoprostol
- Enprostil
("-prazole")
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e